1176758-04-5

1176758-04-5 structure

Name: Otaplimastat
Chemical Name: SP-8203
CAS Number: 1176758-04-5
Molecular Formula: C₂₈H₃₄N₆O₅
Molecular Weight: 534.607
Catalog: Signaling Pathways Membrane Transporter/Ion Channel iGluR
Create Date: 2018-06-23 04:53:29
Modify Date: 2025-08-25 01:24:15
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].

Name	SP-8203
Synonyms	SP-8203 N-[3-(2,4-Dioxo-1,4-dihydro-3(2H)-quinazolinyl)propyl]-N-(4-{[3-(2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl)propyl]amino}butyl)acetamide UYE03B60KA Acetamide, N-[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]-N-[4-[[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]amino]butyl]-

Description	Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> iGluR Signaling Pathways >> Metabolic Enzyme/Protease >> MMP Research Areas >> Neurological Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> iGluR
Target	MMP NMDA
In Vitro	Otaplimastat (87.5-350 μM; 20 min) protects neuronal cells against NMDA-induced cell death in a competitive manner[1]. Otaplimastat (350 μM) inhibits Ca2+ influx following activation of NMDA receptors in primary cultured neuron[1]. Otaplimastat (2-200 μM; pretreated for 4 h) significantly suppresses H2O2-induced cell death and reactive oxygen species production[2].
In Vivo	Otaplimastat (10-20 mg/kg; i.p. 30 min before occlusion and 1 h after reperfusion) prevents ischemic neuronal death in the occlusion model of MCA[1]. Otaplimastat (5-10 mg/kg; i.p. daily for 10 days) attenuates impairment of stroke-induced motor function[2]. Animal Model: Male Wistar rats (280-310 g, 9 weeks) were induced transient middle cerebral artery (MCA) occlusion[1] Dosage: 10, 20 mg/kg Administration: I.p. before 30 min and after an hour of the MCA-occlusion operation Result: Significantly reduced infarct volume. Improved spatial learning and memory impairments.
References	[1]. Noh SJ, et, al. SP-8203 shows neuroprotective effects and improves cognitive impairment in ischemic brain injury through NMDA receptor. Pharmacol Biochem Behav. 2011 Nov;100(1):73-80. [2]. Noh SJ, et, al. SP-8203 reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia. Pharmacol Biochem Behav. 2011 Mar;98(1):150-4. [3]. Kim JS, et, al. Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Ann Neurol. 2020 Feb;87(2):233-245.

Density	1.3±0.1 g/cm3
Molecular Formula	C₂₈H₃₄N₆O₅
Molecular Weight	534.607
Exact Mass	534.259094
LogP	1.76
Index of Refraction	1.589

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

864772-22-5	942938-68-3
190516-03-1	1344051-19-9
1373866-58-0	42514-49-8
1257639-27-2	1343362-76-4
1342089-82-0	1373866-71-7